Beacon Biosignals

Beacon Biosignals is a health technology company that applies machine learning to electroencephalogram (EEG) data to enable and accelerate the development of new treatments for neurological, psychiatric, and sleep disorders. The company's core offerings include SleepStageML, an FDA-cleared software that automatically stages sleep from EEG signals during polysomnography, and the Dreem 3S wearable medical device, which enables validated sleep endpoints collection at home.

SleepStageML leverages advanced deep-learning models trained on massive datasets containing hundreds of thousands of hours of PSG recordings from diverse patient populations. It automates the labor-intensive manual sleep staging process, reduces subjective variability in scoring between human experts, and supports faster PSG analysis turnaround time. SleepStageML is the first sleep-focused medical device cleared by the FDA with a Predetermined Change Control Plan, allowing for continuous improvements to its machine-learning algorithm within the scope of its initial clearance.

Beacon Biosignals' platform provides an architectural foundation for discovery of robust quantitative neurobiomarkers that subsequently can be deployed for patient stratification, automated safety or efficacy monitoring, and as clinical trial endpoints across therapeutic areas such as neurodegenerative disorders, epilepsy, sleep disorders, and mental illness. The company's technology has identified novel electrophysiologic signatures linked to primary cognitive endpoints in Alzheimer's disease and has shown promise in heterogeneous psychiatric diseases such as schizophrenia and major depressive disorder.

In March 2024, Beacon Biosignals announced that it had been acquired by an undisclosed company.